专家点评

专家简介：
Eric Eeckhout1984年毕业于比利时布鲁塞尔自由大学医学院。截至1991年，Eric Eeckhout在该医学院附属医院做心脏科医师，并特别显示了对于介入心脏病学的浓厚兴趣。从1991年开始，他加入瑞士洛桑大学医学院附属医院（CHUV），并于1999年，成为该医院导管室主任。他的临床方向包括：心脏瓣膜病，成人先心病的经皮介入治疗，急性冠脉综合症，冠脉生理学等。在冠脉介入并发症的预防及治疗方面，Eric Eeckhout有极高的学术成就。从1998年开始，他于洛桑创建了国际冠脉介入并发症研讨会。现在是EuroPCR冠脉介入并发症专场的主席。同时，他也是欧洲心脏病学学会（European Society of Cardiology, ESC）大会议程编排委员会成员，也是该组织核心委员会（Focus Committee）成员.
中文评论
Prof. Eric Eeckhout：作为一项新生事物，干细胞移植可能是治疗缺血性心脏病令人激动的新选择。尤其是那些有大面积心肌梗死患者，因其预后不佳，更有可能从细胞移植治疗中获益。但迄今为止，临床试验结果相互矛盾，使临床医师不清楚干细胞治疗的真实作用，从而使得其仍然处于实验性治疗阶段。导致这些试验结果不同的因素很多，其中，杨跃进等于5月2日在European Heart Journal发表的文章为人们提供一个全新视角。作者选取28只中华小型猪，随机分成4组（n=7），结扎左前降支冠脉制作急性前壁心肌梗死模型，在梗死前随机给予阿托伐他汀预处理，和/或梗死后即刻心肌内注射自体骨髓间充质干细胞。分别于梗死后1周和6周时进行MRI和SPECT检测，结果显示阿托伐他汀预处理和干细胞移植联合组的心肌灌注和心功能显著改善，作者推测认为其机制是由于阿托伐他汀抑制凋亡、炎症和氧化应激从而增加干细胞的在体存活。该标志性论文揭示了一个重要信息，即他汀类药物在干细胞治疗中具有潜在益处，因此在未来的干细胞治疗中应考虑推荐使用他汀。同时祝贺作者的杰出研究。
英文评论：
Prof. Eric Eeckhout：
Stem cell therapy is an emerging and exciting potential new treatment option in ischemic heart disease.  In particular, patients who suffer from large myocardial infarction might benefit from cell regeneration as the prognosis is severely impaired.
Clinical trials in this field have shown conflictual and opposite results making it difficult for the clinician to understand the true role of this still experimental therapy.  The results of these trial may be explained by several factors.
The article by Yang et al in the European Heart Journal of May 2 2008 provides further insight into this issue.  The authors studied a total of 28 Chinsese mini-pigs  in whom they created artificially an anterior myocardial infarction.  Before creating the myocardial infarction, the pigs had been randomized to  pretreatment with artovastatin and/or injection of autologous bone marrow mesenchimal cells after the myocardial infarction into a double randomization model, thereby created 4 groups of 7 pigs for analysis.  Six weeks after the intervention, the pigs were studied by MRI and SPECT indicating that in the group of combined artorvastatin pretreatment and stem cell therapy the best perfusion and myocardial contractility.   The authors postulate an effect on apoptosis, oxidative stress and inflammation as possible mechanisms.
This landmark paper reveals important information indicating for the first time to potential beneficial role of statins in the setting of stem cell therapy.  Therefore,  statin therapy should probably be considered in the methodogy of future clinical stem cell trials.
The authors are to be congratulated for their oustanding research.